Academic Jobs - Home of Higher Ed Logo

Menopausal Hot Flashes: University of Victoria Research Offers New Hope Through Insulin Insights

276views
Submit News
woman in black tank top sitting on brown wooden bench
Photo by Annie Botía on Unsplash

Understanding Vasomotor Symptoms: The Core Challenge of Menopause

Menopause marks a significant transition in women's lives, often accompanied by vasomotor symptoms (VMS), which include sudden hot flashes, drenching night sweats, and chilling cold sweats. These symptoms, driven by fluctuating hormone levels particularly declining estrogen, affect approximately 75 percent of women during the menopausal transition. In Canada, where the population is aging, up to 80 percent of women experience some form of menopause symptoms, with 25 percent seeking medical treatment due to their severity. Symptoms can begin as early as two years before the final menstrual period and persist for seven to ten years or longer, disrupting sleep, work, and daily activities.

Hot flashes, for instance, manifest as intense waves of heat spreading across the upper body, often with a racing heart and flushed skin. Night sweats can soak bedding, leading to fatigue, while cold sweats follow as the body overcorrects. These VMS not only impair quality of life but also correlate with broader health risks, including cardiovascular issues and type 2 diabetes. Canadian women, influenced by diverse ethnic backgrounds and lifestyles, report varying experiences—factors like socioeconomic status and ethnicity play roles, with higher prevalence among certain groups.

The economic toll is substantial. Moderate to severe VMS impact work productivity, with surveys showing 14.7 percent of postmenopausal Canadian women experiencing significant symptoms linked to reduced quality of life and professional performance. This underscores the urgency for research into modifiable risk factors.

University of Victoria's Breakthrough: Insulin Levels as a Predictor

Researchers at the University of Victoria (UVic) have uncovered a compelling link between midlife insulin levels and the onset and duration of VMS. Published in January 2026 in The Journal of Clinical Endocrinology & Metabolism, the study titled "Insulin Levels Early in Perimenopause Inform Vasomotor Symptom Incidence Across the Menopausal Transition" reveals that higher fasting insulin at age 47—early perimenopause—predicts earlier starts to hot flashes and night sweats, longer-lasting symptoms, and elevated testosterone trajectories.

University of Victoria biology lab focused on metabolic research

This finding offers new hope by highlighting insulin—a key marker of metabolic health—as a potentially modifiable factor. Unlike fixed traits like genetics, insulin responds to lifestyle, suggesting proactive steps could ease the menopause journey for many Canadian women.

Meet the Minds: Faria Athar and Nicole Templeman Lead the Charge

Lead author Faria Athar, a recent UVic PhD graduate, brings fresh perspectives from her work on metabolic influences on reproduction. "Higher insulin at age 47 was associated with longer durations of hot flashes and cold sweats," Athar notes, emphasizing the study's role in explaining symptom variability.

Senior author Nicole Templeman, Assistant Professor of Biology and Tier 2 Canada Research Chair in Metabolic Determinants of Reproduction and Aging, oversees the Templeman Lab at UVic. Her expertise spans aging biology, insulin signaling, and nutrient pathways using model organisms. Funded by the Canadian Institutes of Health Research and Michael Smith Health Research BC, Templeman's work bridges metabolic and reproductive health, aligning with UN Sustainable Development Goal 3 for better health outcomes.

For aspiring researchers, UVic exemplifies opportunities in Canadian higher education. Explore research jobs or research assistant positions to contribute to fields like this.

Unpacking the Methodology: Leveraging SWAN's Longitudinal Power

The study analyzed data from 704 participants in the Study of Women's Health Across the Nation (SWAN), a landmark U.S.-based longitudinal cohort launched in 1994. SWAN tracks physical, biological, psychological, and social changes during menopause across diverse ethnicities at seven sites.

UVic researchers focused on age-47 fasting insulin and BMI measurements from baseline (ages 42-52) through ten annual visits. Outcomes included VMS timing/duration (hot flashes, night sweats, cold sweats, vaginal dryness) and hormone trajectories (estradiol, FSH, testosterone) relative to the final menstrual period. Cox proportional hazards models assessed risks, controlling for covariates like BMI.

This rigorous approach—approved by UVic's Human Research Ethics Board—provides robust evidence, distinguishing insulin's unique role from BMI's.

Key Results: Quantifying Insulin's Impact on VMS

Higher age-47 insulin independently predicted:

  • Earlier onset of hot flashes and night sweats.
  • Prolonged hot flashes and cold sweats.
  • Greater testosterone increases across transition.

BMI paralleled insulin for VMS but linked more to slower estradiol decline and blunted FSH rise. Insulin's association with hot flashes persisted post-BMI adjustment, underscoring its predictive strength.

In practical terms, women with elevated insulin faced higher VMS hazards, potentially explaining why metabolic health influences symptom severity. Templeman highlights: "Insulin may be elevated early in metabolic disorders, informing menopause symptom incidence."

Canadian Context: Prevalence and Broader Health Implications

In Canada, menopause affects millions, with VMS burdening healthcare and workplaces. A recent survey found 14.7 percent of postmenopausal women reporting moderate/severe VMS, impairing daily function. Ethnic variations mirror SWAN: higher reports among Black women versus Asian.

UVic's findings resonate amid rising metabolic syndrome concerns. VMS severity links to type 2 diabetes risk, amplifying insulin's relevance. For Canadian women, this suggests early screening around age 47 could guide interventions, reducing long-term cardiometabolic risks.

Canadian Menopause Society resources emphasize holistic management, now bolstered by metabolic insights.

Actionable Lifestyle Changes: Lowering Insulin to Combat Hot Flashes

The study's promise lies in insulin's modifiability. Strategies include:

  • Diet: Prioritize low-glycemic foods—leafy greens, berries, nuts, lean proteins, whole grains. Reduce refined carbs/sugars to stabilize blood sugar.
  • Exercise: 150 minutes weekly moderate aerobic (brisk walking, swimming) plus strength training. Even post-meal walks lower insulin spikes.
  • Stress Management: Mindfulness, yoga reduce cortisol, aiding insulin sensitivity.
  • Sleep: Consistent 7-9 hours; avoid caffeine/alcohol evenings.

Exercise lowers insulin without weight loss, offering quick wins. Intermittent fasting or protein-focused meals further support. Consult healthcare providers for personalized plans, especially with prediabetes.

For career advice on health sciences, visit higher ed career advice.

Integrating with Current Treatments: A Comprehensive Approach

Canada's 2021 SOGC guidelines position menopausal hormone therapy (MHT) as gold standard for VMS, reducing frequency by 75-90 percent. Non-hormonal options like SSRIs (citalopram), gabapentin, or fezolinetant provide relief for contraindications.

UVic research complements by advocating metabolic optimization pre-MHT. Lifestyle tweaks enhance efficacy, delay need, or suffice mildly symptomatic women. Fezolinetant, neurokinin B antagonist, targets VMS root without estrogen.

Holistic: cognitive behavioral therapy, acupuncture show modest benefits. Track symptoms via apps; consult SOGC for updates.

Chart showing insulin impact on menopause hormone trajectories

Future Outlook: Expanding UVic's Metabolic-Reproductive Research

Templeman's lab explores insulin signaling in aging/reproduction using C. elegans models, translating to humans. Athar's ongoing work on insulin mitigation in reproductive aging promises more.

Prospective trials testing diet/exercise on VMS via insulin are needed. Broader SWAN analyses could refine ethnic/Canadian specifics. Policy-wise, integrate metabolic screening into midlife checkups.

UVic's contributions position Canada as leader in women's health research. Aspiring academics, rate professors like Templeman on Rate My Professor or pursue university jobs.

Empowering Women Through Science: Next Steps and Resources

This UVic study empowers proactive menopause management, linking everyday metabolic health to symptom control. Monitor insulin via routine bloodwork; adopt sustainable changes early.

For jobs in biology or health research, browse higher ed jobs, faculty positions, or academic CV tips. Share experiences on Rate My Professor. Knowledge is hope—start today.

Portrait of Dr. Oliver Fenton
About the author

Dr. Oliver FentonView author

Academic Jobs In House Author

Acknowledgements:

Discussion

Sort by:

Be the first to comment on this article!

You

Please keep comments respectful and on-topic.

New0 comments

Join the conversation!

Add your comments now!

Have your say

Engagement level

Browse by Faculty

Browse by Subject

Frequently Asked Questions

🔥What are vasomotor symptoms in menopause?

Vasomotor symptoms (VMS) are sudden feelings of heat (hot flashes), night sweats, or cold sweats affecting 75% of women during menopause transition.

🧪How does the UVic study connect insulin to hot flashes?

Higher fasting insulin at age 47 predicts earlier onset and longer duration of hot flashes and night sweats, independent of BMI.

👩‍🔬Who led the University of Victoria menopause research?

Faria Athar (lead author, PhD grad) and Nicole Templeman (Assistant Professor, Canada Research Chair) used SWAN data.

🥗Can lifestyle changes lower insulin for menopause relief?

Yes—diet low in refined carbs, 150 min weekly exercise, stress reduction improve insulin sensitivity, potentially easing VMS.

📊What is the SWAN study?

SWAN is a longitudinal U.S. cohort tracking menopause changes in diverse women since 1994.

🇨🇦How common are hot flashes in Canadian women?

Up to 80% experience symptoms; 14.7% postmenopausal women report moderate/severe VMS impacting quality of life.

💊What are standard treatments for VMS in Canada?

MHT is most effective per SOGC guidelines; non-hormonal like SSRIs, gabapentin for others.

⚖️Does BMI affect menopause symptoms like insulin?

BMI parallels insulin for VMS onset but links more to hormone changes like estradiol decline.

🔮What future research follows UVic's findings?

Trials on insulin-lowering interventions for VMS; Templeman Lab explores metabolic-reproductive links.

🎓How to pursue research careers like at UVic?

Check research jobs or career advice on AcademicJobs.com for biology and health roles.

🌍Are there ethnic differences in VMS per the study?

SWAN data shows variations, e.g., higher in Black vs. Asian women, influenced by location and SES.